Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
US6169091A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 26, 1998 |
| Grant date | Jan 2, 2001 |
| Priority date | — |
| Expiry date | Aug 26, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Substituted heteroaromatic compounds of formula (A) wherein X is N or CH; in which (a) represents a fused 5, 6 or 7-membered heterocyclic ring and R.sup.3 is a group ZR.sup.4 wherein Z is joined to R.sup.4 through a (CH.sub.2)p group in which p is 0, 1, or 2 and Z represents a group V(CH.sub.2), V(CF.sub.2), (CH.sub.2)V, (CF.sub.2)V, V(CRR'), V(CHR) or V where R and R' are each C.sub.1-4 alkyl and in which V is a hydrocarbyl group containing 0, 1 or 2 carbon atoms, carbonyl, dicarbonyl, CH(OH), CH(CN), sulphonamide, amide, O, S(O).sub.m or NR.sup.b where R.sup.b is hydrogen or R.sup.b is C.sub.1-4 alkyl; and R.sup.4 is an optionally substituted C.sub.3-6 cycloalkyl or an optionally substituted 5, 6, 7, 8, 9 or 10-membered carbocyclic or heterocyclic moiety; or R.sup.3 is a group ZR.sup.4 in which Z is NR.sup.b, and NR.sup.b and R.sup.4 together form an optionally substituted 5, 6, 7, 8, 9 or 10-membered carbocyclic or heterocyclic moiety, are protein tyrosine kinase inhibitors. The compounds are described, as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of psoriasis, fibrosis, atheros…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.